Ibrahim Al-Zakwani 6 hospitalizations (35% vs. 41%) and revascularization procedures (16% vs. 22%) than those treated with atorvastatin 10 mg. Post-hoc analysis of coronary artery bypass graft surgery (CABG) patients from the TNT trial showed intensive LDLcholesterol lowering to a mean of 2.05 mmol/l with atorvastatin 80 mg/day decreased major cardiovascular events significantly by 27% and the need for repeat coronary revascularization by 30%, compared to atorvastatin 10 mg/day.
Introduction
Dysl ipidemia is a strong risk factor for myocardial infarction, 1 and serum cholesterol concentrations have been shown to be directly related to mortality from coronary heart disease (CHD). [2] [3] [4] Lower low-density lipoprotein cholesterol (LDL-C) blood concentrations are associated with lower cardiovascular disease risk, reduction in peripheral vascular disease, and reduction in both fatal and non-fatal vascular events as shown by the Heart Protection Study. 5 Several randomized controlled trials enrolling a wide variety of patients confirmed that for every 1 mmol/L reduction in serum LDL-C by statin treatment, the relative risks of cardiovascular events and mortality are decreased by 21% and 12% respectively. 6 Several recent studies have shown that intensive LDL-C lowering of <1.8 mmol/L in patients with coronary heart disease decreased cardiovascular events significantly. [7] [8] [9] In the Treating to New Targets (TNT) study, patients who received atorvastatin 80mg had 22% relative risk reduction in major cardiovascular events, fewer additional coronary artery disease (CAD)-related coronary syndrome) LDL-C should decrease below 1.8 mmo/l as an optional target. 12 European guidelines recommend a target LDL-C of <2.5 mmol/L in patients with CAD. The American and Canadian guidelines on the other hand, recommend a target LDL-C of < 2.0 mmol/L in these patients.
This study was conducted to evaluate the safety and the effectiveness of achieving LDL-C targets with Simvastatin according to the NCEP-ATP III guidelines in patients with different risk categories at Sultan Qaboos University Hospital.
Methods
This study was a retrospective chart review carried out between April 2008 and May 2008. Patients on simvastatin were identified by reviewing prescriptions provided by the outpatient pharmacy department. Patients were included if they were >18 years of age, and completed a minimum of three months simvastatin therapy. Patients were classified into mild, moderate and high risks for cardiovascular event according to NCEP-ATP-III guidelines based on the presence of one or more cardiovascular risk factors, presence of diabetes, and calculated Framingham risk score. Patients were excluded if they received combination of lipid lowering agents.
The results of lipid values (total cholesterol (TC), triglycerides (TG), LDL-C and HDL-C) were measured at SQU biochemistry laboratory. TC and TG were measured by enzymatic, colorimetric methods. HDL-C and LDL-C were measured by homogeneous enzymatic colorimetric methods. Lipid results were obtained from the laboratory information system before statin treatment and a minimum of 3 months after treatment.
Adverse events were obtained from laboratory data (measurements of ALT and CK). No clinical signs or symptoms were reviewed.
For categorical variables, frequencies and percentages were reported and for continuous variables, means and standard deviations (±SD) were presented. Mean differences between groups were analyzed using paired t-tests. An a priori two-tailed level of significance was set at the 0.05 level. Statistical analysis was performed using STATA version 9.1 software.
Results
224 prescriptions were reviewed over one week. A total of 160 patients were included (78 males and 82 females). A total of 64 patients were excluded; 44 patients of whom used simvastatin for <3 months, 14 patients were shifted from fluvastatin to simvastatin, 2 patients were <18 years and 4 patients used simvastatin with fenofibrate.
Baseline characteristics of all patients are summarized in Table   1 . Mean age was 57±12 years, and mean weight 73.4±15.9 kg. 72 patients (45%) were diagnosed with cardiovascular disease and codiagnoses with myocardial infarction and angina being the most common diagnoses. 80 patients (50%), had diagnosis of DM (2 with type 1 DM, 78 with type 2 DM), 107 (67%) had hypertension, 4(2.5%) were smokers and 5(3%) had family history of CAD. The majority of patients were high risk patients (75%). 7% of the patients were moderate risk and 18% were low risk. Duration of treatment was >12 months in 113 (71%) and between 3-12 months in 47 (29%) of the patients. Almost all patients received simvastatin dose of 20 mg in (98%) and 40 mg dose in only 2% of the patients.
LDL-C concentration prior to simvastatin treatment (preindex) was available for 58 (36%) patients, 79 (49%) patients for post-treatment (post-index) and for 30 (19%) pre and post index. Table 2 summarizes the lipid profile at baseline and post treatment for the 160 patients according to their risk groups. LDL-C concentration decreased significantly for all groups after treatment (3.60±1.03 to 3.25±1.34 mmol/L). The mean LDL-C in the high risk group was 4.11±1.06 mmol/L pre-treatment and 3.38±1.28 mmol/L post-treatment. 
Discussion
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) sets LDL-C as the primary target for cholesterol lowering therapy. LDL-C should be lowered to <2.60 mmol/L in patients with established CAD or CAD risk equivalents like DM and other CVDs.
12 LDL-C of ≤1.8 mmol/L is an optional target for patients with CAD with multiple major or uncontrolled risk factors like DM, smoking and obesity. 12 In this study, 43% of the high risk patients achieved LDL-C target of <2.6 mmol/L. Compared to other studies, data from the Lipid Treatment Assessment Project (L-TAP) study showed an overall 37% of high risk patients achieved NCEP-specified LDL-C target level. 13 In the L-TAP study, the success rate for the high risk patients on simvastatin was 50%. This is still a low percentage for LDL-C attainment. Also, it was observed that 49% of patients had no post-index LDL-C level to be evaluated.
The reasons for low percentage of goal achievement in general may result from initiating at the wrong dose, inappropriate choice of drug, physician not adhering to guidelines, drug tolerability by patients and noncompliance. In the current study, patient compliance was not examined, but it was apparent that 49% of patients had no post-index LDL-C level to be evaluated which could partly be explained by physicians not adhering to guidelines or poor patient compliance. It was also revealed that 71% of the patients were on simvastatin for >12 months and 98% were on a low starting dose of 20 mg. The doses of simvastatin were not titrated to a maximum dose to reach the LDL-C targets. The mean LDL-C at baseline for the high risk group was higher than the LDL-C levels in low and moderate risk groups. To achieve LDL-C target of <2.6 mmol/L in this group, LDL-C should be decreased at least by 40% and simvastatin at 40 mg would be an appropriate starting dose.
The updated NCEP-ATP3 guidelines specify LDL-C <1.8 mmol/L as an optional target for CHD with multiple risk factors. These recommendations indicate using even a higher dose of statin, more potent statin or combination with fibrate, niacine, bile acid sequestrant or ezetimibe, should be considered as starting therapy for these patients. In patients with multiple risk factors and at a high risk for CHD, ezetimibe added to statin was markedly superior to placebo added to statin in achievement of NCEP ATP II LDL-C treatment goals (72% vs. 19%, p<0.001).
14 At relative starting doses, 10 mg ezetimibe/20 mg simvastatin once daily has been shown to lower LDL-C levels more than atorvastatin at its starting doses of 10 mg or 20 mg once daily. At the highest doses, 10 mg ezetimibe/80 mg simvastatin lowers LDL-C more than atorvastatin 80 mg per day. 15 Although conflicting data exists regarding the effect of ezetimibe when added to statin on atherosclerosis progression, still it is considered as an effective drug in lowering cholesterol. 16, 17 The efficacy of colesevelam, a unique bile acid sequestrant has been evaluated in combination with statins. 18 The administration of 6 tablets of colesevelam with statins has been shown to result in an approximate 10-16% further reduction in LDL-C levels, favorable effects upon HDL-C levels, and mild to moderate elevations in triglyceride levels. 19, 20 The combination of niacin with statins have complementary benefits on multiple lipoprotein parameters, especially HDL.
In the ADvicor Versus Other Cholesterol-modulating Agents Trial Evaluation (ADVOCATE), the combination of niacin ER plus lovastatin was more effective than either atorvastatin or simvastatin alone in increasing LDL peak particle diameter and was more effective than either atorvastatin or simvastatin alone in increasing the proportion of HDL in "cardio protective" 2b subclass. 21 Additionally, the combination of niacin and simvastatin lowered LDL-C levels by 42%, increased HDL-C by 26% and reduced CHD events by 60-90 %. 22 During the period of this study, simvastatin and fenofibrate were the only medications available at SQUH. In the Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (SAFARI) trial, combination therapy of fenofibrate 160 mg and simvastatin 20 mg resulted in additional decreased TG by 43%, increased HDL-C by 18.6% and decreased LDL-C by 31.2% compared to simvastatin 20 mg monotherapy. 23 Higher rate of drug-related adverse events were also observed. Only patients on simvastatin monotherapy were evaluated and patients on combination therapy were excluded in this study.
Common side effects associated with the use of statins are elevated aminotransferase levels >3 times the upper limit of normal, (incidence of <1% in low-moderate statins dose and 2-3% in higher dose). These elevations are related to the dose of statins but not to the reduction of LDL-C. Severe liver injury is rare and the elevation of the aminotransferases is most often transient and will resolve spontaneously in 70% of cases even if the statins and doses are continued unchanged. The cause of elevation in liver transaminase levels is not well understood but proposed mechanisms, including a transient pharmacologic effect secondary to cholesterol reduction in hepatocytes, comorbid conditions such as diabetes mellitus and obesity, and the consumption of alcohol or non-statin medications. The most prevalent side effect with statin therapy is myalgia (1.5-3%). Serious muscle toxicity and rhabdomyolysis are rare (occurs in 5 patients per 100,000 personyears and rhabdomyolysis in 1.6 patients per 100,000 personyears).
The National Lipid Association Statin Safety Assessment Task Force does not recommend routine measurement of CK levels in asymptomatic patients during the course of statin therapy, because marked clinically important CK elevations are rare and are usually related to physical exertion or other causes. 24 In this study, there were no significant increases in liver enzymes and CK levels in patients treated with simvastatin.
Conclusion
Overall, this study showed that more than half of the high risk patients are not at target for LDL-C goals which place them at a continuous risk for CHD and their lipid lowering therapy using statins or combination therapy should be optimized to improve the chances of achieving LDL-C goals.
